Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Summary
Ranibizumab is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels.1
Clinical Trials
| nAMD | |||
|---|---|---|---|
| Phase | Enrollment Status | Title | |
| Phase III | Enrolling | A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor-Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration | View Details |
| Phase IV | Enrolling | A Phase IV, Multicenter, Open-Label Study to Assess Corneal Endothelial Cells in Patients with Neovascular Age-Related Macular Degeneration Treated with the Port Delivery System with Ranibizumab | View Details |
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT
-
DME
diabetic macular edema